Tissue sample collection from patients with neuroendocrine tumor (NET) treated with peptide receptor radionuclide therapy (PRRT) for future blood disease research

#3176

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for patients with metastatic NET. However, the development of therapy-related myeloid neoplasms (t-MN) is an infrequent but serious complication. T-MN after PRRT occurs at higher frequency compared to other solid tumor chemotherapies and harbour unfavourable genetic mutations with poor treatment outcomes. Prospective data is needed to explore pre-existing genetic factors and predictive biomarkers to minimise t-MN risk.

Aim(s): To collect and store blood and bone marrow samples from patients with NET treated with PRRT for use in future blood disease research.

Materials and methods: Patients referred to Peter MacCallum Centre Center (ENETS Center of Excellence) for PRRT or Peptide Receptor Chemoradionuclide Therapy (PRCRT) will be eligible for participation in this single centre study. Study samples will be taken in two phases. During phase 1, 9 ml peripheral blood will be taken at each 3 time-points (pre-PRRT, prior to last induction cycle, and 12 months after last induction cycle) for DNA/RNA extraction and serum separation. Samples will be stored frozen at the haematology and molecular facility at the centre. Phase 2 will only apply to patients if there is suspicion of t-MN requiring haematology review and bone marrow biopsy; 5ml peripheral blood (for serum separation) and bone marrow tissue (for DNA/RNA extraction) will be collected at the time of bone marrow biopsy and stored.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kong G

Authors: Kong G, Michael M, Alipour R, Akhurst T, Hicks R,

Keywords: t-MN, PRRT, PRCRT, marrow biopsy,